Patient & Visitor InformationContact Us
  • RI Hospital Study: Graft Occlusion in Hemodialysis Patients

  • RI Hospital Study:
    Graft Occlusion in Hemodialysis Patients

    Rhode Island Hospital is seeking patients to participate in a phase I trial with plasmin to evaluate the safety and to select the doses of phase II in patients with hemodialysis graft occlusion.

    Plasmin is a direct thrombolytic agent developed as a potential therapeutic agent for the treatment of hemodialysis patients with thrombosed arterio-venous shunts.

    Patients or individuals interested in taking part in this trial should be on chronic hemodialysis with a graft that now is occluded or has gone down.

    For more information, or to refer a patient, please contact the vascular interventional radiology department at 401-444-5194.